Suchergebnisse - "Hynes, Scott M"

PubPharm (11)

1

Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Patnaik, A. | Gordon, M. | Tsai, F. | +11

2

A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer

enthalten in: Cancer chemotherapy and pharmacology | 2018

von Patnaik, A. | Gordon, M. | Tsai, F. | +11

3

Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer

enthalten in: Cancer chemotherapy and pharmacology | 2017

von Infante, J. | Patnaik, A. | Verschraegen, C. | +14

4

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

enthalten in: Investigational new drugs | 2016

von Scagliotti, G. | Kang, J. | Smith, D. | +14

5

Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors

enthalten in: Oncology | 2016

von Calvo, E. | Braiteh, F. | Von Hoff, D. | +11

6

Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors

enthalten in: Anti-cancer drugs | 2015

von Doi, T. | Yoshino, T. | Shitara, K. | +7

7

Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients

enthalten in: Biopharmaceutics & drug disposition | 2015

von Hynes, S. | Wickremsinhe, E. | Zhang, W. | +4

8

Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors

enthalten in: Xenobiotica | 2014

von Wickremsinhe, E. | Hynes, S. | Palmieri, M. | +6

9

Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer

enthalten in: Investigational new drugs | 2014

von Calvo, E. | Chen, V. | Marshall, M. | +15

10

Importance of Peptide Transporter 2 on the Cerebrospinal Fluid Efflux Kinetics of Glycylsarcosine Characterized by Nonlinear Mixed Effects Modeling

enthalten in: Pharmaceutical research | 2013

von Huh, Y. | Hynes, S. | Smith, D. | +1